跳至主要内容
临床试验/JPRN-jRCTb030230286
JPRN-jRCTb030230286招募中1 期

The safety and efficacy of autologous peripheral blood mononuclear cell ex vivo culture amplified cells (MNC-QQ) for alopecia: Phase 1 / 2 clinical study - Phase 1/2 clinical trial using MNC-QQ for alopecia

Ikeda Yoshio0 个研究点目标入组 5 人开始时间: 2023年8月10日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 < 75age old(—)
性别
All

入选标准

  • 1. Patients with written informed consent.
  • 2. Patiens are at the age of 18 to 75 at the time of informed consent.
  • 3. Patients affected alopecia and want to receive regenerative therapy.

排除标准

  • 1. Patients with HbA1c(NGSP) more than 10.0 with the medication for diabetes.
  • 2. Patients with systemic infection.
  • 3. Patients with severe anemia.
  • 4. Patients with malignancy, or within 5 years after recover from malignant tumor (10 years after breast cancer), except for cutaneous basal cell carcinoma.
  • 5. Patients with hematopoietic disorders such as leukemia, myeloproliferative disease, marrow dysplasia syndrome.
  • 6. Pregnant women.
  • 7. Patients infected with HIV, active HBV, HCV, HTLV, or syphilis in screening test.
  • 8. Patients not expect to live for a year or more.
  • 9. Patients enrolled in any other clinical trial within 90 days before informed consent.
  • 10. Patients who can't consent not to change medication.
  • 11. Any other reason that the Clinical Researchers may have for considering a case unsuitable for the study.

研究者

发起方
Ikeda Yoshio

相似试验